



# SHIFTING THE NEEDLE IN ASCVD

IT'S NOW EVEN  
EASIER TO PRESCRIBE  
**LEQVIO** WITH

**STREAMLINED  
AUTHORITY**



## Entresto and Leqvio GP Slide Deck: Shifting the needle in ASCVD

Shifting the needle in ASCVD

Image

## Shifting the needle in ASCVD



### **GP Entresto/Leqvio Slide Deck (Format: Powerpoint)**

Powerpoint

[Download](#)

Image

## Shifting the needle in ASCVD



### **GP Entresto/Leqvio Slide Deck (Format: PDF)**

PDF

[Download](#)

**ENTRESTO PBS Information:** Authority required (STREAMLINED) for chronic heart failure. Patients must be NYHA Class II-IV, have LVEF  $\leq 40\%$  and be receiving optimal standard chronic heart failure treatment. Refer to PBS Schedule for full Authority Information.

For LEQVIO (inclisiran) prescribing information, please **click here**.

**LEQVIO PBS Information:** Authority Required (STREAMLINED) for patients with hypercholesterolaemia. Refer to PBS Schedule for full Authority information.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at **[www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems)**.

For LEQVIO (inclisiran) prescribing information, please **click here**.

This content is intended for Australian healthcare professionals and is promotional.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc. Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. Sydney NSW.

For medical enquiries please contact 1800 671 203 or **[medinfo.phauno@novartis.com](mailto:medinfo.phauno@novartis.com)**.

---

**Source URL:**

*<https://www.pro.novartis.com/au-en/entresto-and-leqvio-gp-slide-deck-changing-course-cardiovascular-disease>*